The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 442-447

  Luminari, Stefano ^a   Biasoli, I ^b   Versari, A ^c   Rattotti, S ^d   Bottelli, C ^e   Rusconi, C ^f   Merli, F ^c   Spina, M ^g   Ferreri, A J M ^h   Zinzani, P L ⁱ   Gallamini, A ^j   Franceschetto, A ^a   Boccomini, C ^k   Franceschetti, S ^l   Salvi, F ^m   Raimondo, F D ⁿ   Carella, A M ^o   Micol, Q ^a   Balzarotti, M ^p   Musto, P ^q   Federico, M ^a   more..

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c S MARIA NUOVA HOSPITAL   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e SPEDALI CIVILI   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ Institute of Hematology Seràgnoli   (Italy)

^j S CROCE E CARLE HOSPITAL   (Italy)

^k CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^l UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^m Hematology Unit AO SS Antonio e Biagio e Cesare Arrigo   (Italy)

ⁿ UNIVERSITY OF CATANIA   (Italy)

^o UNIVERSITY OF GENOA   (Italy)

^p HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^q REFERRAL CANCER CENTER OF BASILICATA   (Italy)

more..

Author keywords

FDG PET; Follicular lymphoma; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; DIAGNOSTIC USE; KAPLAN MEIER METHOD; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCINTISCANNING; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84893372842     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt562     Document Type: Article

References (17)

1. Freedman A. Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol 2012; 87: 988-995.
2. Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579-4586.
3. Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-1992.
4. Salles G, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-4831.
5. Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-3732.
6. Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51.
7. Solal-Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
8. Federico M, Vitolo U, Zinzani PL et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783-789.
9. Ladetto M, De Marco F, Benedetti F et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008; 111: 4004-4013.
10. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
11. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
12. Luminari S, Biasoli I, Arcaini L et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol 2013; 24: 2108-2112.
13. Trotman J, Fournier M, Lamy T et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol 2011; 29: 3194-3200.
14. Dupuis J, Berriolo-Riedinger A, Julian A et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J Clin Oncol 2012; 30: 4317-4322.
15. Federico M, Luminari S, Dondi A et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 2013; 31: 1506-1513.
16. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
17. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 3875-3876.